Infliximab: A treatment option for ulcerative pyoderma gangrenosum

Sasha M. Geren, Francisco A. Kerdel, Anna F. Falabella, Robert Kirsner

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an uncommon inflammatory disorder characterized by painful skin ulcers. Often treated with corticosteroids, antibiotics with anti-inflammatory properties, and/or immunosuppressive medications, PG may be difficult to treat. The authors performed a retrospective analysis of patients with refractory PG treated with infliximab at a dose of 5mg/kg. Five patients were treated. Infliximab was efficacious in all, with healing of 12 of 13 ulcers in a mean time of 12.2 weeks. Patients received a range of one to three infusions (mean 1.8). In conclusion, infliximab is a treatment option for PG.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalWounds
Volume15
Issue number2
StatePublished - Feb 1 2003

Fingerprint

Pyoderma Gangrenosum
Skin Ulcer
Therapeutics
United States Food and Drug Administration
Immunosuppressive Agents
Crohn Disease
Ulcer
Rheumatoid Arthritis
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Infliximab
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Surgery

Cite this

Geren, S. M., Kerdel, F. A., Falabella, A. F., & Kirsner, R. (2003). Infliximab: A treatment option for ulcerative pyoderma gangrenosum. Wounds, 15(2), 49-53.

Infliximab : A treatment option for ulcerative pyoderma gangrenosum. / Geren, Sasha M.; Kerdel, Francisco A.; Falabella, Anna F.; Kirsner, Robert.

In: Wounds, Vol. 15, No. 2, 01.02.2003, p. 49-53.

Research output: Contribution to journalArticle

Geren, SM, Kerdel, FA, Falabella, AF & Kirsner, R 2003, 'Infliximab: A treatment option for ulcerative pyoderma gangrenosum', Wounds, vol. 15, no. 2, pp. 49-53.
Geren SM, Kerdel FA, Falabella AF, Kirsner R. Infliximab: A treatment option for ulcerative pyoderma gangrenosum. Wounds. 2003 Feb 1;15(2):49-53.
Geren, Sasha M. ; Kerdel, Francisco A. ; Falabella, Anna F. ; Kirsner, Robert. / Infliximab : A treatment option for ulcerative pyoderma gangrenosum. In: Wounds. 2003 ; Vol. 15, No. 2. pp. 49-53.
@article{97d77fb866cd4c03abfe613dfef7d975,
title = "Infliximab: A treatment option for ulcerative pyoderma gangrenosum",
abstract = "As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an uncommon inflammatory disorder characterized by painful skin ulcers. Often treated with corticosteroids, antibiotics with anti-inflammatory properties, and/or immunosuppressive medications, PG may be difficult to treat. The authors performed a retrospective analysis of patients with refractory PG treated with infliximab at a dose of 5mg/kg. Five patients were treated. Infliximab was efficacious in all, with healing of 12 of 13 ulcers in a mean time of 12.2 weeks. Patients received a range of one to three infusions (mean 1.8). In conclusion, infliximab is a treatment option for PG.",
author = "Geren, {Sasha M.} and Kerdel, {Francisco A.} and Falabella, {Anna F.} and Robert Kirsner",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "15",
pages = "49--53",
journal = "Wounds",
issn = "1044-7946",
publisher = "HMP Communications",
number = "2",

}

TY - JOUR

T1 - Infliximab

T2 - A treatment option for ulcerative pyoderma gangrenosum

AU - Geren, Sasha M.

AU - Kerdel, Francisco A.

AU - Falabella, Anna F.

AU - Kirsner, Robert

PY - 2003/2/1

Y1 - 2003/2/1

N2 - As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an uncommon inflammatory disorder characterized by painful skin ulcers. Often treated with corticosteroids, antibiotics with anti-inflammatory properties, and/or immunosuppressive medications, PG may be difficult to treat. The authors performed a retrospective analysis of patients with refractory PG treated with infliximab at a dose of 5mg/kg. Five patients were treated. Infliximab was efficacious in all, with healing of 12 of 13 ulcers in a mean time of 12.2 weeks. Patients received a range of one to three infusions (mean 1.8). In conclusion, infliximab is a treatment option for PG.

AB - As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an uncommon inflammatory disorder characterized by painful skin ulcers. Often treated with corticosteroids, antibiotics with anti-inflammatory properties, and/or immunosuppressive medications, PG may be difficult to treat. The authors performed a retrospective analysis of patients with refractory PG treated with infliximab at a dose of 5mg/kg. Five patients were treated. Infliximab was efficacious in all, with healing of 12 of 13 ulcers in a mean time of 12.2 weeks. Patients received a range of one to three infusions (mean 1.8). In conclusion, infliximab is a treatment option for PG.

UR - http://www.scopus.com/inward/record.url?scp=0037291837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037291837&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037291837

VL - 15

SP - 49

EP - 53

JO - Wounds

JF - Wounds

SN - 1044-7946

IS - 2

ER -